Medical - Vaccine Guide 2022 - 19

Appendix
Vaccine
Dengue (DEN4CYD)
Diphtheria, tetanus, pertussis (DTaP)
Tetanus, diphtheria (DT)
Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2022
Precautions2
Contraindications1
* Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
* Severe immunodeficiency (e.g., hematologic and solid tumors, receipt of chemotherapy, congenital
immunodeficiency, long- term immunosuppressive therapy or patients with HIV infection who are severely
immunocompromised)
* Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
* For DTaP only: Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) not
attributable to another identifiable cause within 7 days of administration of previous dose of DTP or DTaP
* Pregnancy
* HIV infection without evidence of severe immunosuppression
* Moderate or severe acute illness with or without fever
* Guillain-Barré syndrome (GBS) within 6 weeks after previous dose of tetanus-toxoid-containing vaccine
* History of Arthus-type hypersensitivity reactions after a previous dose of diphtheria-toxoid- containing
or tetanus-toxoid- containing vaccine; defer vaccination until at least 10 years have elapsed since the last
tetanus-toxoid- containing vaccine
* For DTaP only: Progressive neurologic disorder, including infantile spasms, uncontrolled epilepsy,
progressive encephalopathy; defer DTaP until neurologic status clarified and stabilized
Haemophilus influenzae type b (Hib)
Hepatitis A (HepA)
Hepatitis B (HepB)
Hepatitis A- Hepatitis B vaccine
[HepA-HepB, (Twinrix®)]
Human papillomavirus (HPV)
Measles, mumps, rubella (MMR)
* Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
* For Hiberix, ActHib, and PedvaxHIB only: History of severe allergic reaction to dry natural latex
* Less than age 6 weeks
* Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
neomycin
* Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
* For Heplisav-B only: Pregnancy
* Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
neomycin and yeast
* Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
* Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
* Severe immunodeficiency (e.g., hematologic and solid tumors, receipt of chemotherapy, congenital
immunodeficiency, long-term immunosuppressive therapy or patients with HIV infection who are severely
immunocompromised)
* Pregnancy
* Family history of altered immunocompetence, unless verified clinically or by laboratory testing as
immunocompetent
Meningococcal ACWY (MenACWY)
[MenACWY-CRM (Menveo®);
MenACWY-D (Menactra®);
MenACWY-TT (MenQuadfi®)]
Meningococcal B (MenB)
[MenB-4C (Bexsero®);
MenB-FHbp (Trumenba®)]
Pneumococcal conjugate (PCV13)
Pneumococcal polysaccharide
(PPSV23)
Poliovirus vaccine, inactivated (IPV)
Rotavirus (RV) [RV1 (Rotarix®),
RV5 (RotaTeq®)]
Tetanus, diphtheria, and acellular
pertussis (Tdap)
Tetanus, diphtheria (Td)
* Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
* For MenACWY-D and Men ACWY-CRM only: severe allergic reaction to any diphtheria toxoid- or CRM197-
containing vaccine
* For MenACWY-TT only: severe allergic reaction to a tetanus toxoid-containing vaccine
* Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
* Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
* Severe allergic reaction (e.g., anaphylaxis) to any diphtheria-toxoid- containing vaccine or its component3
* Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
* Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
* Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
* Severe combined immunodeficiency (SCID)
* History of intussusception
* Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
* For Tdap only: Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) not
attributable to another identifiable cause within 7 days of administration of previous dose of DTP, DTaP, or
Tdap
Varicella (VAR)
* Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a vaccine component3
* Severe immunodeficiency (e.g., hematologic and solid tumors, receipt of chemotherapy, congenital
immunodeficiency, long- term immunosuppressive therapy or patients with HIV infection who are severely
immunocompromised)
* Pregnancy
* Family history of altered immunocompetence, unless verified clinically or by laboratory testing as
immunocompetent
* For MenACWY-CRM only: Preterm birth if less than age 9 months
* Moderate or severe acute illness with or without fever
* Pregnancy
* For MenB-4C only: Latex sensitivity
* Moderate or severe acute illness with or without fever
* Moderate or severe acute illness with or without fever
* Moderate or severe acute illness with or without fever
* Pregnancy
* Moderate or severe acute illness with or without fever
* Altered immunocompetence other than SCID
* Chronic gastrointestinal disease
* RV1 only: Spina bifida or bladder exstrophy
* Moderate or severe acute illness with or without fever
* Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of tetanus-toxoid-containing vaccine
* History of Arthus-type hypersensitivity reactions after a previous dose of diphtheria-toxoid- containing
or tetanus-toxoid- containing vaccine; defer vaccination until at least 10 years have elapsed since the last
tetanus-toxoid- containing vaccine
* For Tdap only: Progressive or unstable neurological disorder, uncontrolled seizures, or progressive
encephalopathy until a treatment regimen has been established and the condition has stabilized
* Moderate or severe acute illness with or without fever
* Recent (≤11 months) receipt of antibody-containing blood product (specific interval depends on product)
* Receipt of specific antiviral drugs (acyclovir, famciclovir, or valacyclovir) 24 hours before vaccination (avoid
use of these antiviral drugs for 14 days after vaccination)
* Use of aspirin or aspirin-containing products
* Moderate or severe acute illness with or without fever
1. When a contraindication is present, a vaccine should NOT be administered. Kroger A, Bahta L, Hunter P. ACIP General Best Practice Guidelines for Immunization. www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html
2. When a precaution is present, vaccination should generally be deferred but might be indicated if the benefit of protection from the vaccine outweighs the risk for an adverse reaction. Kroger A, Bahta L, Hunter P. ACIP General Best Practice
Guidelines for Immunization. www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html
3. Vaccination providers should check FDA-approved prescribing information for the most complete and updated information, including contraindications, warnings, and precautions. Package inserts for U.S.-licensed vaccines are available at
www.fda.gov/vaccines-blood-biologics/approved-products/vaccines-licensed-use-united-states.
22MS6015
19
henryschein.com/medical
including
including yeast
including
* Moderate or severe acute illness with or without fever
* Moderate or severe acute illness with or without fever
* Moderate or severe acute illness with or without fever
* Moderate or severe acute illness with or without fever
* Moderate or severe acute illness with or without fever
* Moderate or severe acute illness with or without fever
* Recent (≤11 months) receipt of antibody-containing blood product (specific interval depends on product)
* History of thrombocytopenia or thrombocytopenic purpura
* Need for tuberculin skin testing or interferon-gamma release assay (IGRA) testing
* Moderate or severe acute illness with or without fever
http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html http://www.fda.gov/vaccines-blood-biologics/approved-products/vaccines-licensed-use-united-states http://www.henryschein.com/medical
Medical - Vaccine Guide 2022

Table of Contents for the Digital Edition of Medical - Vaccine Guide 2022
